Pre-existing anti thyroid peroxidase antibodies are associated with improved prognosis in patients with advanced NSCLC receiving the PD-1 inhibitors nivolumab or pembrolizumab (48). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.